Stem definition | Drug id | CAS RN |
---|---|---|
4233 | 343306-71-8 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 0.18 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.28 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.53 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 25, 2008 | EMA | MERCK SHARP & DOHME LIMITED | |
Dec. 15, 2015 | FDA | ORGANON USA INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Recurrence of neuromuscular blockade | 178.85 | 51.37 | 22 | 1161 | 81 | 50603860 |
Anaphylactic reaction | 158.87 | 51.37 | 56 | 1127 | 53999 | 50549942 |
Bronchospasm | 104.49 | 51.37 | 30 | 1153 | 14824 | 50589117 |
Bradycardia | 103.37 | 51.37 | 43 | 1140 | 64383 | 50539558 |
Anaphylactic shock | 99.65 | 51.37 | 31 | 1152 | 20124 | 50583817 |
Neuromuscular block prolonged | 71.02 | 51.37 | 12 | 1171 | 499 | 50603442 |
Clonus | 60.72 | 51.37 | 15 | 1168 | 4160 | 50599781 |
Hyperreflexia | 57.68 | 51.37 | 15 | 1168 | 5103 | 50598838 |
Maternal exposure during pregnancy | 54.39 | 51.37 | 38 | 1145 | 159740 | 50444201 |
Hypoventilation | 51.57 | 51.37 | 13 | 1170 | 3908 | 50600033 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic reaction | 171.62 | 69.86 | 55 | 946 | 27518 | 29546008 |
Anaphylactic shock | 163.55 | 69.86 | 45 | 956 | 13291 | 29560235 |
Recurrence of neuromuscular blockade | 147.45 | 69.86 | 20 | 981 | 118 | 29573408 |
Negative pressure pulmonary oedema | 137.85 | 69.86 | 20 | 981 | 203 | 29573323 |
Bronchospasm | 106.50 | 69.86 | 30 | 971 | 9579 | 29563947 |
Cardiac arrest | 99.35 | 69.86 | 51 | 950 | 85540 | 29487986 |
Neuromuscular block prolonged | 88.09 | 69.86 | 15 | 986 | 448 | 29573078 |
Bradycardia | 81.52 | 69.86 | 41 | 960 | 65588 | 29507938 |
Kounis syndrome | 78.67 | 69.86 | 17 | 984 | 1812 | 29571714 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic reaction | 292.73 | 46.96 | 103 | 2069 | 68561 | 64427999 |
Recurrence of neuromuscular blockade | 230.08 | 46.96 | 31 | 2141 | 173 | 64496387 |
Anaphylactic shock | 228.05 | 46.96 | 70 | 2102 | 30258 | 64466302 |
Bradycardia | 153.33 | 46.96 | 76 | 2096 | 118143 | 64378417 |
Neuromuscular block prolonged | 147.67 | 46.96 | 26 | 2146 | 951 | 64495609 |
Bronchospasm | 145.79 | 46.96 | 46 | 2126 | 21636 | 64474924 |
Negative pressure pulmonary oedema | 137.49 | 46.96 | 20 | 2152 | 207 | 64496353 |
Cardiac arrest | 128.96 | 46.96 | 74 | 2098 | 153990 | 64342570 |
Oxygen saturation decreased | 82.90 | 46.96 | 49 | 2123 | 107127 | 64389433 |
Kounis syndrome | 80.53 | 46.96 | 19 | 2153 | 3006 | 64493554 |
Hypoventilation | 72.17 | 46.96 | 20 | 2152 | 5986 | 64490574 |
Delayed recovery from anaesthesia | 59.01 | 46.96 | 13 | 2159 | 1515 | 64495045 |
Hypotension | 55.59 | 46.96 | 66 | 2106 | 380908 | 64115652 |
Maternal exposure during pregnancy | 51.88 | 46.96 | 35 | 2137 | 95849 | 64400711 |
Clonus | 49.70 | 46.96 | 15 | 2157 | 6052 | 64490508 |
Laryngospasm | 48.50 | 46.96 | 13 | 2159 | 3432 | 64493128 |
Hyperreflexia | 47.27 | 46.96 | 15 | 2157 | 7133 | 64489427 |
None
Source | Code | Description |
---|---|---|
ATC | V03AB35 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
FDA CS | M0081434 | gamma-Cyclodextrins |
CHEBI has role | CHEBI:51372 | neuromuscular agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Reversal of neuromuscular blockade | indication | 241703000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.58 | acidic |
pKa2 | 7.94 | acidic |
pKa3 | 8.0 | acidic |
pKa4 | 8.0 | acidic |
pKa5 | 8.0 | acidic |
pKa6 | 8.0 | acidic |
pKa7 | 8.0 | acidic |
pKa8 | 8.0 | acidic |
pKa9 | 13.29 | acidic |
pKa10 | 13.65 | acidic |
pKa11 | 13.89 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | RE44733 | Jan. 27, 2026 | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK |
EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | RE44733 | Jan. 27, 2026 | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | June 9, 2023 | REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4 |
EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | June 9, 2023 | REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4 |
EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | June 25, 2024 | NEW PATIENT POPULATION |
EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | BRIDION | ORGANON SUB MERCK | N022225 | Dec. 15, 2015 | RX | SOLUTION | INTRAVENOUS | June 25, 2024 | NEW PATIENT POPULATION |
None
ID | Source |
---|---|
D05940 | KEGG_DRUG |
343306-79-6 | SECONDARY_CAS_RN |
4035288 | VANDF |
C1700695 | UMLSCUI |
CHEBI:90953 | CHEBI |
CHEMBL2111107 | ChEMBL_ID |
CHEMBL2107374 | ChEMBL_ID |
D000077122 | MESH_DESCRIPTOR_UI |
DB06206 | DRUGBANK_ID |
8528 | INN_ID |
361LPM2T56 | UNII |
6918584 | PUBCHEM_CID |
1726987 | RXNORM |
159483 | MMSL |
26064 | MMSL |
31376 | MMSL |
31381 | MMSL |
d07361 | MMSL |
012914 | NDDF |
012915 | NDDF |
1172425006 | SNOMEDCT_US |
442340006 | SNOMEDCT_US |
442379000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
BRIDION | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5423 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 29 sections |
BRIDION | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5423 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 29 sections |
BRIDION | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5425 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 29 sections |
BRIDION | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0006-5425 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 29 sections |
BRIDION | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71872-7187 | INJECTION, SOLUTION | 100 mg | INTRAVENOUS | NDA | 28 sections |